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Histopathological features of gastrointestinal mucosal biopsies in children with 
juvenile idiopathic arthritis. 
 
Abstract 
Objective: The association between inflammatory bowel disease and joint 
involvement is well established but there is a paucity of data describing 
histopathological features of the gut in relation to juvenile idiopathic arthritis (JIA).  
Methods: We retrospectively identified 34 (22 male) children aged from 3-16 years 
with JIA (12 oligoarthritis, 5 polyarthritis, 8 systemic onset arthritis, 8 enthesis-related 
arthritis and 1 psoriatic arthritis) with significant gastrointestinal symptoms who 
underwent upper and/or lower endoscopy between 2002-2009. The histopathological 
findings at the time of endoscopy were reviewed in addition to gastrointestinal 
symptoms, presence of autoantibodies and concomitant treatment. 
Results: In these 34 children the most common gastrointestinal indications for 
endoscopy were persistent abdominal pain 15/34 (44%) and diarrhoea 11/44 (32%). 
29/34 (85%) had gut mucosal inflammation, mostly affecting the colon (80%). Active 
inflammation of the gut was found in 6/29 (21%) children with one child presenting 
with features typical of inflammatory bowel disease, 15/29 (52%) showed mild non-
specific inflammation. Eight patients (27%) had predominantly an eosinophilic 
inflammation. Twenty-six of 34 had previously received treatment for JIA. There was 
a negative association with the use of immunomodulators and the presence of 
eosinophil inflammation. 
Conclusion: The majority of children with JIA and gastrointestinal symptoms have 
histological evidence of mild non-specific inflammation, but some having active 
colitis and prominent eosinophil infiltrate.  
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What is Known about this topic 
 Arthritis occurs in 7-25% of children with IBD and may precede the onset of 
gastrointestinal symptoms.  
 Given the association between gut and joint inflammation, little is known 
about the features of gut inflammation in these children with juvenile 
idiopathic arthritis. 
 
What This Study Adds: 
 There are histological abnormalities in children with JIA with gastrointestinal 
symptoms.  
 The predominant pathological findings were a varying severity of mucosal 
inflammation ranging from chronic inflammation to active chronic inflammation. In 
addition eosinophils were a prominent component. 
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ABBREVIATIONS 
CD- Crohn´s disease, UC- ulcerative colitis, IBD- inflammatory bowel disease, EIM- 
extraintestinal manifestation, HPF- high power field, RA- rheumatoid arthritis, JIA- 
juvenile idiopathic arthritis, RF- rheumatoid factor, Th- T helper type, ANA- anti-
nuclear antibodies, EGID- eosinophilic gastrointestinal disorders  
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INTRODUCTION 
Crohn´s disease (CD) or ulcerative colitis (UC), collectively known as inflammatory 
bowel disease (IBD) are chronic idiopathic conditions of the gastrointestinal tract with 
nearly one quarter of cases having onset during childhood or adolescent years [1]. 
Several studies in adult populations have described increased co-morbidity with other 
immune-mediated diseases including asthma, arthritis, rheumatoid arthritis (RA), 
ankylosing spondylitis and psoriasis [1-6]. A paediatric study described a particularly 
strong association of IBD with RA and systemic lupus in children compared with 
previous adult studies [1].  
Arthritis is a common extraintestinal manifestation (EIM) of several conditions 
including IBD, bacterial or parasitic infections of the gut, coeliac disease and 
pseudomembranous colitis. Arthritis is the most frequent EIM, occurring in 7-25% of 
children with IBD that may precede the onset of gastrointestinal symptoms by years 
[7,8]. It appears to be more prevalent in patients with large bowel than small bowel 
disease and in those with complications such as abscesses, pseudomembranous 
polyposis, perianal disease, massive haemorrhage, erythema nodosum, stomatitis, 
uveitis, and pyoderma gangrenosum [9].   
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in 
childhood and is an important cause of short and long-term disability. It is a clinical 
diagnosis made in a child less than 16 years of age with arthritis (defined as swelling 
or limitation of motion of the joint accompanied by heat, pain, or tenderness) for at 
least 6 weeks' duration with other identifiable causes of arthritis excluded, the 
physical findings may be associated with raised inflammatory markers and positive 
findings on radiology. Studies in developed countries have reported a prevalence that 
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varies between 16 and 150 per 100000 [10]. The International League of Association 
for Rheumatology classification of JIA includes seven subtypes: 
Systemic onset JIA, oligoarticular JIA, polyarticular rheumatoid factor (RF)-positive 
and RF-negative JIA, Enthesis-related JIA, psoriatic JIA and others or unclassified 
[11]. 
Several clues for the close linkage between gut and joint inflammation have been 
suggested. Alterations in key molecules that regulate the immune response in the gut 
of patients with enthesis-related JIA arthritis are similar to those with CD [12]. 
Changes commonly found in both groups are a high expression of E-cadherin in the 
gut or toll- like receptors, a T helper type1 (Th1) predominance in the intestinal 
mucosa, increased proportion of Th17 cells or dysfunction of regulatory T cells [12]. 
The alteration in function and regulation of these molecules may have an important 
role in initiation of these diseases. Additionally, increased intestinal permeability has 
been reported in patients with spondyloarthropathy and IBD, which may alter the 
local immune response to bacterial antigens or abnormal responses to certain 
microorganisms [12]. 
Given the well-known association between gut and joint inflammation, surprisingly 
little is known about the features of gut inflammation in this group of children with 
severe joint disease. Mielants et al [13] described 12 patients less than sixteen years of 
age with late-onset juvenile chronic arthritis who had undergone colonoscopy with 
biopsies of the colonic mucosa and terminal ileum and gut inflammation was 
demonstrated in nine (75%). Kokkonen et al [14] examined the prevalence of immune 
activation in gastrointestinal mucosa in children with JIA or connective tissue disease 
and found that the majority of children suffering from JIA or CTD with GI symptoms 
show abnormalities consistent with activation of the intestinal immune system such as 
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UC or lymphoid nodular hyperplasia, as well in the duodenal bulb, terminal ileum and 
colon with specific CD 3 lymphocytes in the intestine. Arvonen et al [15,16] could 
demonstrate that intestinal gamma/delta- intraepithelial lymphocytes are increased in 
children with JIA and suggested that lymphocyte cytotoxicity is abnormally increased 
in the intestinal mucosa in JIA. 
The aim of this study is to evaluate gastrointestinal mucosal histopathological features 
in a series of children with juvenile idiopathic arthritis who underwent endoscopic 
evaluation for significant gastrointestinal symptoms.  
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METHODS 
Patients referred to a paediatric gastroenterology centre during the period January 
2002 to December 2009 who underwent gastrointestinal endoscopy for 
gastrointestinal symptoms with JIA were retrieved from hospital databases. All cases 
of JIA who had endoscopic examination were identified and medical records were 
analysed retrospectively. The diagnosis for JIA was made by experienced paediatric 
Rheumatologists and classified using International League of Association for 
Rheumatology criteria [17].  
Children with JIA with significant bowel symptoms were referred for further 
evaluation usually by either upper and/or lower endoscopy. Significant 
gastrointestinal symptoms included diarrhoea, constipation, vomiting, abdominal 
pain, weight loss, oral aphthous ulcers or per-rectal bleeding.  
 
Demographic data at the time of endoscopy were sex, age at start of JIA and age when 
endoscopy was performed. In addition to basic demographics, specific types of JIA, 
types of treatment patients were on at the time of endoscopy; presence of 
autoantibodies (anti-nuclear antibodies (ANA) and rheumatoid factor (RF)) and HLA-
B27 association were reviewed.    
All children who underwent endoscopy had routine mucosal biopsies taken from 
oesophagus, stomach, duodenum, terminal ileum and colon (caecum, ascending colon, 
transverse colon, descending colon, sigmoid colon and rectum) following the 
departmental protocol. Routine formalin fixation, paraffin embedding and sectioning 
of 4 µm thick sections was performed followed by haematoxylin and eosin staining.  
All biopsy specimens were reviewed by a panel, including a consultant Paediatric 
Pathologist, a clinical scientist with a PhD in paediatric GI pathology, a scientist 
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whose research area is GI mucosal disease and a consultant academic paediatric 
gastroenterologist with an interest in inflammatory disease.  
Histological features were recorded and compared to the clinical information. For the 
purposes of this paper there were 4 categories of GI biopsy finding: (1) normal, (2) 
mild non-specific inflammation, (3) mild inflammation with prominent eosinophils 
(4) active inflammation. Eosinophilic oesophagitis was defined by the presence of 
more than 15 eosinophils per HPF [18]. In the colon, although no consensus exists, 
we considered 30 eosinophils per HPF in the caecum and 20 eosinophils per HPF in 
the left colon as normal values [19, 20]. 
 
To compare endoscopy results especially the incidence of eosinophilia a control group 
was used. It included 35 children (19 or 54% male, mean age 7.9 ±3.6 years (range: 
2.8 to 15 years) with intractable constipation (defined as per ESPGHAN guidelines 
[21] as chronic constipation not responding to optimum medical therapy for at least 3 
months) have undergone endoscopy.  
The baseline characteristics of all patients were evaluated by means of simple 
descriptive analysis. Continuous variables were presented as median, minimum and 
maximum values and categorical data as absolute frequencies and proportions. As 
univariate analyses Χ2 test or Fisher exact test were used to compare the different 
types of JIA or inflammation and location of inflammation. Spearman’s rho test was 
used when appropriate. Statistical analyses were performed using SPSS (version 20.0 
Mac; SPSS, Chicago, IL). All statistical tests were 2 tailed using 0.05 level of 
significance. The study was approved by the local ethical committee as a retrospective 
review / audit.  
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RESULTS 
Study cohort 
We identified 34 children (22 or 65% male) with a diagnosis of JIA who had 
undergone endoscopy for gastrointestinal symptoms. The median age of onset of JIA 
was 6.4 years (range: 1.5 to 15.8 years). The median age at time of endoscopy was of 
9.2 years (range 3.3 to 16.3 years). The type of JIA was oligoarticular JIA in 12 (35%) 
cases, polyarticular JIA in 5 (15%) cases, systemic onset JIA in 8 (24%) cases and, 
enthesis-related arthritis in 8 (24%) cases JIA and psoriatic JIA in one (2%) child 
(Table 1).  
The most common gastrointestinal indications for endoscopy were persistent 
abdominal pain 15/34 (44%), diarrhoea 11/44 (32%), faltering growth or weight loss 
6/34 (17%), per-rectal bleeding 5/34 (15%) and other less common gastrointestinal 
symptoms were mouth ulcers, haematemesis or constipation. (Figure 1). There was 
no association between the clinical gastrointestinal symptoms and type of JIA using 
univariate analyses.  
In 27 (80%) children an upper and lower endoscopy was performed. In 3 (9%) 
children an upper endoscopy only and in 4 (12%) children only a lower endoscopy 
was performed. Histological examination of gut mucosal biopsies demonstrated some 
gut inflammation in 29/34 (85%) with 5/34 (15%) having normal histology (Table 2). 
There were significant more children with gut inflammation in JIA group compared to 
the control group with 8/35 (22%) children, p<0.001. 
 
In the upper endoscopy the inflammation was mostly located in the duodenum in 
11/29 (38%), stomach in 8/29 (27%), and in 3/29 (10%) both stomach and duodenum 
was affected.  
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In the lower endoscopy inflammation was mostly located in the colon in 25/29 (80%) 
of cases; no child had isolated inflammation in the terminal ileum. In 3/29 (9%) cases 
both colon and ileum was affected.  
In our cohort of patients with abnormal histological features, the majority of children 
with 11/29 (38%) had involvement of the colon only, 4/29 (14%) had involvement of 
duodenum and colon, 4/29 (14%) of stomach, duodenum and colon (2 of those 
included inflammation of the terminal ileum), 2/29 (7%) of stomach and colon and 
one case of involvement of oesophagus and colon.  
 
Active inflammation was present in 6/29 (21%) children. One child had a new 
diagnosis of CD at the time of endoscopy where the joint disease was the primary 
presentation. 15/29 (52%) intestinal mucosal biopsies showed non-specific 
inflammation and 9 of the 29 patients (27%) had mild inflammatory changes with 
predominant eosinophils (Figure 1). In 5 cases this involved only the colon, in two 
cases involved TI and colon, and in two cases involved the duodenum and colon.  
In the control group 8/35 (22%) had eosinophilic infiltrate not significant to the JIA 
patients, in all cases exclusively in the colon.  
There was no direct correlation between the types of JIA, gut inflammation, type of 
gut inflammation, clinical symptoms and treatment using Χ2 test.  
 
 
In 28/34 serum autoantibody levels were available. Of the 11/28 (39%) patients with 
abnormal gut histology, anti-nuclear antibodies were positive in 7/28 (25%) of the 
patients and rheumatoid factor were positive in 4/28 (14%) cases (2 cases systemic 
JIA, one case with polyarticular JIA and one case with enthesis-related arthritis). No 
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gut-specific autoantibodies had been performed. We did not observe any direct 
correlation between autoantibodies positivity and types of gut inflammation using 
univariate analyses.  
26/34 received treatment for JIA. One (3%) child of the 29 patients with abnormal 
histology was on steroids only, 4/29 (13%) patients were on steroids and 
immunomodulators namely azathioprine and methotrexate, 2/29 (7%) patients were 
on non steroidal anti-inflammatory drugs (NSAID) and immunomodulators, 7/29 
(24%) were on immunomodulators only, and one (3%) child was on tumor necrosis 
factor inhibitor (etanercept) at the time of the endoscopy. In addition, there were 4 
(13%) children on NSAID and 2 (7%) on sulfasalazine (Table 1 and 2). Overall 8 
(27%) of the 29 children with abnormal histology were not on treatment at the time of 
endoscopy. 
Amongst the group of 5 patients with normal histology, one (20%) child was off 
treatment, two (40%) were on steroids and immunomodulators, one (20%) on 
immunomodulators only and 2 (40%) were on sulfasalazine.  
When immunomodulators were used no abnormal eosinophilic infiltrate was 
identified compared to 7 children with no treatment that had eosinophilic infiltration 
(p=0.01). No other association of the immunosuppressive therapy with chronicity of 
the inflammation or the type of inflammation could be found using univariate 
analyses. 
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DISCUSSION 
The findings of this study have described the histological abnormalities seen in 
routine gastrointestinal mucosal biopsies in children with JIA juvenile idiopathic 
arthritis with significant gastrointestinal symptoms. The predominant pathological 
findings were a varying severity of mucosal inflammation ranging from mild non-
specific inflammation to chronic inflammation. In addition eosinophils were a 
prominent component. 
 
More than 80% of our cohort of children had abnormal mucosal gut inflammation 
despite almost half of them having been on immunomodulators at the time of 
endoscopy. The majority showed colonic inflammation, a finding similar to the 
previous observation of arthritis as an extraintestinal manifestation occurring more 
commonly in CD patients with large bowel evolvement [22,23]. 
 
There was no correlation between gut inflammation and sub-type of JIA. There were 
more boys than girls in this group of patients despite JIA being commoner in girls 
[24]. This can be explained by the larger number of systemic-onset JIA with 24% 
(where the sex incidence is equal) and also 24% enthesitis related arthritis patients 
(where boys are more often affected than girls). Most cohorts of JIA patients would 
have around 10% systemic onset patients and around 10-15% enthesitis related 
arthritis patients. This cohort had 24% systemic onset and 24% enthesitis related 
arthritis patients. This could have been due to small numbers and so by chance, or GI 
symptoms may be commoner in these JIA sub-types.  
Another speculation about over-representation of systemic onset or enthesitis related 
arthritis could be that in most of the cases, intestinal symptoms precede or coexist 
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with joint manifestations, but in some patients, arthritis precedes the gut 
manifestations, even by several years [12]. This could be investigated further by 
prospectively collecting data on GI symptoms in a large cohort of JIA patients. Why 
there were a high number of ERA patients with gut involvement remains unclear. 
Enthesitis and dactylitis in IBD patients have been studied less well than peripheral 
arthritis [25]. The prevalence of enthesitis in patients with IBD varies from 5 to 10%, 
is predominantly seen in Crohn's disease [26].  
Prior studies have established altered microbiota and immunologic reactivity to 
enteric commensal organisms in IBD. Stoll et al. found in children with enthesitis-
related JIA a reduced abundance of faecalibacterium in the stool [27]. Differences in 
the humoral responses to these bacteria may contribute to disease. So ERA patients 
may also have altered microbiota and immune responsiveness to enteric organisms 
which could influence gut inflammation [27], however, we do no have any data about 
microbiota to support this.  
 
 
Acute inflammation occurred in 6 of 29 patients with abnormal histology. Nine out of 
15 patients with mild non-specific inflammation had been on immunomodulators that 
might have modified their disease activity hence presenting with a much less severe 
picture. Prevalence of active IBD inflammatory bowel disease could potentially have 
been even higher.  
It was previously noted that in adults with ankylosing spondylitis, 5-10% have 
inflammatory bowel disease [23]. Approximately 30%-60% patients with 
spondyloarthropathies have occult intestinal inflammation, which may be related to 
their ingestion of non-steroidal anti-inflammatory drugs or associated with their 
rheumatic disease [22]. In a prospective study of 123 patients with 
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spondyloarthropathies who initially underwent endoscopy, intestinal evolution was 
evaluated by ileocolonoscopy and an evolution to IBD was recorded in 7% of these 
patients [28]. Despite the high frequency of gut lesions in patients with joint diseases, 
only a few patients are symptomatic. In a series described by Cuvelier et al [29], only 
27% of patients with histological gut inflammation had intestinal symptoms. In our 
cohort of JIA children who had undergone endoscopy, all have had significant 
gastrointestinal symptoms with only a minority having normal histological findings, 
though there was no correlation with sub-type of JIA. This study cannot comment on 
the prevalence of subclinical gut inflammation in JIA patients who have no 
gastrointestinal symptoms.  
 
In nearly 30% eosinophilic gut mucosal inflammation was present in our cohort of 
children with JIA and in our control group with 22%. Kokkkonen et al [14] found that 
intraepithelial CD3+, α/ß+, and γ/δ+ lymphocytes counts were increased in children 
with JIA compared to a control group. The aetiology of this reaction remains 
unknown, but similar features are seen in delayed-type food allergy. In line with this, 
Arvonen found that the number of Granzyme B expressing intraepithelial 
lymphocytes was increased in duodenal mucosa in patients with JIA, hence 
lymphocyte cytotoxicity is abnormally increased in the intestinal mucosa in JIA. 
Similar pattern of activation has been seen in food allergy and celiac disease [15,16]. 
Not also food allergy, but also allergy to medications such as NSRAI might be an 
explanation. Arvonen et al [15,16] speculated that some luminal, possibly a nutritional 
factor may be involved in JIA as well. In 22% of our children of the controll group 
with intractable constipation showed eosinophilic infiltrate. In what way our high 
eosinophilic infiltrate in the gut mucosa could play a role with the previous findings 
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remains still unclear. But it could be spectulated that a direct or indirect activation 
from intraepithelial lymphocyty might be an explanation but further studies are 
needed to see whether cytotoxic activation plays any role in the pathogenesis of JIA. 
A high percentage of nearly 30% eosinophilic gut mucosal inflammation was present 
in our cohort. There were only 2 previous case reports describing association of 
eosinophilic gut disease with rheumatoid arthritis in adults [30,31]. The mechanism 
for the eosinophilic gastrointestinal disorders (EGID) in JIA remains to be established 
as well the definition of eosinophilic infiltrate in the gut mucosa. A histological 
finding of eosinophil infiltration (6 cells - high power field (HPF)) in the lamina 
propria was thought to be a useful threshold for diagnosis of food protein-induced 
proctocolitis  [32,33]. However, DeBrosse et al. recently described that eosinophils 
(mean 16-20 cells- HPF) were normally observed in the gastrointestinal tract of 
control children, especially in the colon [34]. Functional studies of EGID are lacking 
and much needed to understand the physiology and pathophysiological roles of 
eosinophils in the gastrointestinal tract [35].  
 
Management of EGID is comprehensive and may involve routine endoscopies. with 
biopsies, dietary modifications, and long-term oral medications. It is not uncommon 
for patients to be put on an elimination diet in an attempt to remove suspected 
pathogenic foods from the diet. In severe cases, amino acid-based elemental formulas 
may serve as the sole source of nutrition [24]. Anti-inflammatory steroid drugs have 
been widely used to treat EGID [25]. Steroid-dependent or steroid-refractory patients 
may be treated with thiopurines (azathioprine or 6-mercaptopurine) [25]. Other 
management strategies include anti-allergic drugs such as mast cell stabiliser 
disodium cromoglycate and leukotriene antagonist montelukast. Ketotifen and H1-
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antihistamines have been shown to reduce tissue eosinophilia and its symptoms in 
patients with EG [26]. Treating these children with JIA with simple dietary 
manipulation, in severe cases amino acid-based elemental formulas, anti-histamines 
and/or thiopurines (azathioprine or 6-mercaptopurine) may be helpful in the 
management of their gastrointestinal symptoms [36-38]. In our children there was a 
negative association with the use of immunomodulators and the presence of 
eosinophilic infiltrate in the intestinal mucosa. Therefore in these patients an earlier 
start of treatment with immunodulators might be reasonable.   
 
There are some limitations in this retrospective study. Firstly, this is a highly selected 
group of children with JIA seen at a tertiary who have gastrointestinal symptoms. This 
does not represent the whole spectrum of disease in children with JIA. Secondly, there 
was no direct (blood test) or indirect (faecal calprotectin) evaluation of mucosal 
inflammation. 
 
In conclusion, our study has described gut mucosal inflammation in children with JIA 
who presented with gastrointestinal symptoms in a tertiary centre. Hereby we could 
confirm previous findings and continued to suggest that endoscopy with mucosal 
biopsies should remain an important investigation for these children. In addition, we 
could find a high percentage of eosinophilic infiltrate in the intestinal mucosa. The 
aetiology of this reaction remains unknown, with several possible explanations such 
as in delayed-type food allergy, allergy to medications such as NSRAI or a pathologic 
infiltration of intraepithelial lymphocytes. In what way the high eosinophilic infiltrate 
in the gut mucosa could play a role with the previous findings remains still unclear. 
Further studies are needed to see whether cytotoxic activation plays any role in the 
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pathogenesis of JIA and to understand the physiology and pathophysiological roles of 
eosinophils in the gastrointestinal tract.  
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FIGURE LEGEND 
 
Figure 1.  
Photomicrographs of colonic mucosal biopsies from children with JIA 
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TABLE Legend 
 
Table 1.  
Demographics at endoscopy 
 
Table 2.  
JIA patients with abnormal gut histology, JIA types, gastrointestinal symptoms and treatment 
 
 
 
